CIK 0001609809
- Non-accelerated filer
- Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 274326290
- Phone
- +1 617-945-9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $795
- in 4 filings, $795 under 10b5-1 plans
Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-15 | DesRosier Thomas Chief Legal Officer and EVP | Exercise or conversion 10b5-1 | +10,625 | 124,516 | ||
| 2024-02-15 | DesRosier Thomas Chief Legal Officer and EVP | Exercise or conversion · Restricted Stock Units 10b5-1 | −10,625 | 31,875 | ||
| 2024-02-15 | Shaff Eric D. CEO and President | Exercise or conversion 10b5-1 | +31,250 | 146,870 | ||
| 2024-02-15 | Shaff Eric D. CEO and President | Exercise or conversion · Restricted Stock Units 10b5-1 | −31,250 | 93,750 | ||
| 2024-02-15 | Henn Matthew R. | Exercise or conversion 10b5-1 | +11,250 | 67,606 | ||
| 2024-02-15 | Henn Matthew R. | Exercise or conversion · Restricted Stock Units 10b5-1 | −11,250 | 33,750 | ||
| 2024-02-15 | Young Teresa L. | Exercise or conversion 10b5-1 | +10,625 | 19,079 | ||
| 2024-02-15 | Young Teresa L. | Exercise or conversion · Restricted Stock Units 10b5-1 | −10,625 | 31,875 | ||
| 2024-02-15 | von Moltke Lisa | Exercise or conversion 10b5-1 | +11,875 | 21,388 | ||
| 2024-02-15 | von Moltke Lisa | Exercise or conversion · Restricted Stock Units 10b5-1 | −11,875 | 35,625 | ||
| 2024-02-15 | Ege David S. | Exercise or conversion 10b5-1 | +11,875 | 78,866 | ||
| 2024-02-15 | Ege David S. | Exercise or conversion · Restricted Stock Units 10b5-1 | −11,875 | 35,625 | ||
| 2024-02-15 | Arkowitz David Chief Financial Officer | Exercise or conversion 10b5-1 | +10,625 | 186,381 | ||
| 2024-02-15 | Arkowitz David Chief Financial Officer | Exercise or conversion · Restricted Stock Units 10b5-1 | −10,625 | 31,875 | ||
| 2024-02-14 | DesRosier Thomas Chief Legal Officer and EVP | Grant or award · Stock Option (Right to Buy) 10b5-1 | +213,750 | 213,750 | ||
| 2024-02-14 | DesRosier Thomas Chief Legal Officer and EVP | Grant or award · Stock Option (Right to Buy) 10b5-1 | +287,905 | 287,905 | ||
| 2024-02-14 | DesRosier Thomas Chief Legal Officer and EVP | Grant or award · Restricted Stock Units 10b5-1 | +35,625 | 35,625 | ||
| 2024-02-14 | Shaff Eric D. CEO and President | Grant or award · Stock Option (Right to Buy) 10b5-1 | +637,500 | 637,500 | ||
| 2024-02-14 | Shaff Eric D. CEO and President | Grant or award · Stock Option (Right to Buy) 10b5-1 | +822,580 | 822,580 | ||
| 2024-02-14 | Shaff Eric D. CEO and President | Grant or award · Restricted Stock Units 10b5-1 | +106,250 | 106,250 |
Page 15 of 23 · 458 trades